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Abstract
Background: S100 calcium binding protein A8 (S100A8) has been implicated as a prognostic indicator in several
types of cancer. However, previous studies are limited in their ability to predict the clinical behavior of the cancer.
Here, we sought to identify a molecular signature based on S100A8 expression and to assess its usefulness as a
prognostic indicator of disease progression in non-muscle invasive bladder cancer (NMIBC).
Methods: We used 103 primary NMIBC specimens for microarray gene expression profiling. The median follow-up
period for all patients was 57.6 months (range: 3.2 to 137.0 months). Various statistical methods, including the
leave-one-out cross validation method, were applied to identify a gene expression signature able to predict the
likelihood of progression. The prognostic value of the gene expression signature was validated in an independent
cohort (n = 302).
Results: Kaplan-Meier estimates revealed significant differences in disease progression associated with the
expression signature of S100A8-correlated genes (log-rank test, P < 0.001). Multivariate Cox regression analysis
revealed that the expression signature of S100A8-correlated genes was a strong predictor of disease progression
(hazard ratio = 15.225, 95% confidence interval = 1.746 to 133.52, P = 0.014). We validated our results in an
independent cohort and confirmed that this signature produced consistent prediction patterns. Finally, gene
network analyses of the signature revealed that S100A8, IL1B, and S100A9 could be important mediators of the
progression of NMIBC.
Conclusions: The prognostic molecular signature defined by S100A8-correlated genes represents a promising
diagnostic tool for the identification of NMIBC patients that have a high risk of progression to muscle invasive
bladder cancer.
Background
Non-muscle invasive bladd e rc a n c e r( N M I B C )i st h e
most common histological subtype of bladder cancer,
accounting for approximately 80% of all cases. Approxi-
mately 20% of these patients experience disease progres-
sion to muscle invasive bladder cancer (MIBC) after
treatment, a development that is associated with a very
poor prognosis for survival. Conventional histopathologi-
cal parameters, such as tumor stage or grade, are gener-
ally considered to be prognostic factors, and numerous
biomarkers have been investigated as prognostic
indicators of the likelihood that NMIBC will develop
into MIBC [1-6].
Members of the S100 family of calcium-binding pro-
teins play essential roles in epithelial tissues and partici-
pate in a wide range of cellular processes, including
transcription, proliferation, and differentiation [7-11]. At
least 16 genes that encode members of the S100 family,
including the gene for S100A8, are clustered on human
chromosome 1q21 [12,13], in a region that frequently
experiences chromosomal rearrangement during tumor
development [14,15]. S100A8 is reportedly up-regulated
in many cancers, including bladder cancer [16-23], and
has been implicated in the regulation of tumor cell pro-
liferation and metastasis [16,24-26]. * Correspondence: wjkim@chungbuk.ac.kr
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investigated as indicators of the risk of disease progres-
sion [1-6], none are able to sufficiently predict the beha-
vior of NMIBC [1-6]. S100A8 has been suggested to be
a predictive biomarker of bladder cancer outcome in
several studies [21-23], however, the regulation of
S100A8 gene expression and whether the genes asso-
ciated with its expression provides additional insight
into the mechanisms of disease progression or tumor
invasion have not been studied. Therefore, we analyzed
the expression pattern of S100A8 and its correlated
genes to assess whether their molecular signature could
identify patients with a higher likelihood of disease
progression.
Methods
Patients and tissue samples
Primary NMIBC tissue samples from 103 consecutive
cases of patients with histologically diagnosed transi-
tional cell carcinoma were obtained from Chungbuk
National University Hospital. To reduce confounding
factors for affecting the analyses, any patients diagnosed
with a concomitant carcinoma in situ (CIS) lesion or
only CIS lesion were excluded. All tumors were macro-
dissected, typically within 15 minutes of surgical resec-
tion. Each bladder cancer specimen was confirmed as
representative by analysis of adjacent tissue in fresh fro-
zen sections from transurethral resection (TUR) speci-
mens, and then frozen in liquid nitrogen and stored at
-80°C until use. The collection and analysis of all sam-
ples was approved by the Institutional Review Board of
Chungbuk National University, and informed consent
was obtained from each subject.
Tumors were staged and graded according to the 2002
TNM classification and the 2004 WHO grading system,
respectively [27]. A second TUR was performed 2-4 week
after the initial resection when it was incomplete or
when a high-grade or T1 tumor was detected [27].
Patients with intermediate- or high-risk NMIBC received
one cycle of intravesical BCG [27,28]. All patients were
followed and managed according to the standard recom-
mendation for treatment of NMIBC [27-29]. In this
study, we defined progression of the disease as an
increase in stage from either Ta or T1 to T2 or higher
after disease relapse [30].
RNA extraction, microarray experiments, and data
processing
Total RNA was isolated by TRIzol reagent (Life Technol-
ogies, NY), according to the manufacturer’sp r o t o c o l .
The quality and integrity of the RNA were confirmed by
agarose gel electrophoresis and ethidium bromide stain-
ing, followed by visual examination under ultraviolet
light. Five-hundred nanograms of total RNA were used
for labeling hybridization according to the manufacturer’s
protocols (Illumina HumanWG-6 BeadChip, version 2).
Arrays were scanned with an Illumina Bead Array Reader
confocal scanner (BeadStation 500GXDW; Illumina, Inc.,
San Diego, CA) according to the manufacturer’s instruc-
t i o n s .A f t e rs c a n n i n g ,t h em i c r o a r r a yd a t aw e r en o r m a l -
ized using quantile normalization in the R language
environment (version 2.8.1, available at http://www.
r-project.org/). Measured gene expression values were
log2 transformed and median centered across genes and
samples. The full microarray data set is available in the
NCBI Gene Expression Omnibus public database under
the data series accession number GSE13507.
Statistical analysis
To classify patients into two groups, we used the med-
ian gene expression value of S100A8 as the cut-off.
Pearson correlation coefficients were calculated to evalu-
ate the association between S100A8 and its correlated
genes. A hierarchical clustering algorithm, using the
uncentered correlation coefficient as the measure of
similarity and average linkage clustering, was applied as
described in Eisen et al [31]. The Kaplan-Meier method
was used to calculate the time to progression, and dif-
ferences between the times was assessed using log rank
statistics. The prognostic value of the S100A8-correlated
gene signature was determined with multivariate Cox
proportional hazard regression models.
To validate the expression signature of S100A8 and its
correlated genes identified in our original cohort, we
applied it to independent microarray data from 302
patients with NMIBC, reported by Dyrskjot et al [32].
For validation of the prognostic value of the molecular
signature, we developed prediction models using the
compound covariate predictor [33], Bayesian compound
covariate predictor [33], linear discriminator analysis
[34], nearest centroid classification [34], and support
vector machines [35]. The models incorporated genes
that were differentially expressed between the two
classes using a two-sample t-test. Genes were considered
to have statistically significant differences in expression
if the P-value was less than 0.001. We estimated the
prediction error of each model using leave-one-out
cross-validation (LOOCV), as described by Simon et al
[36]. For each LOOCV training set, the entire model-
building procedure was repeated, including the gene
selection process. Validation procedure was performed
in BRB ArrayTools (version 3.7.1).
To explore the relationships between S100A8-corre-
lated genes, we examined functional associations among
the genes and generated gene networks based on
whether they had more interconnected genes than
would be expected to occur by chance. The significance
of each network was estimated using the scoring system
provided by the Ingenuity Pathway Analysis Tool (ver-
sion 7.5). The scores were determined by the number of
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works and the strength of the associations among the
network members.
Results
Baseline characteristics
Table 1 details the baseline characteristics of the 103
primary NMIBC patients. The median age was 66.0
years (range: 24 to 88 years), and the median follow-up
period after surgery was 57.6 months (range: 3.2 to
137.0 months). During the follow-up period, 11 of the
103 (10.7%) experienced disease progression.
Prognostic utility of S100A8-correlated genes
We analyzed 103 NMIBC samples and divided them
into two groups according to the expression level of
S100A8. The frequency of progression was significantly
higher in the group with S100A8 expression levels in
the upper 50th percentile than in the group with
S100A8 expression levels in the lower 50th percentile
(log-rank test, P = 0.003; Figure 1-A and 1-B).
W en e x ts o u g h tt oi d e n t i f yag e n ee x p r e s s i o ns i g n a -
ture that directly correlated with S100A8 expression
levels during disease progression and then use that sig-
nature to predict the likelihood of tumor progression.
We identified 1,015 genes whose change in expression
correlated with S100A8 expression (Pearson correlation
test, P < 0.001, r < -0.3 or r > 0.3). Based on hierarchical
clustering analysis of the expression patterns of these
genes, we divided the NMIBC samples into two groups:
high S100A8 cluster (HSC) and low S100A8 cluster
(LSC). The progression rate of HSC patients was signifi-
cantly higher than that of the LSC patients (log-rank
test, P < 0.001; Figure 2).
To evaluate the prognostic efficacy of the newly iden-
tified signature, we applied multivariate Cox regression
analysis to the signature and known clinical and patho-
logic prognostic factors for NMIBC (Table 2). This
analysis revealed that the molecular signature of
S100A8-correlated genes (hazard ratio 15.225, 95% con-
fidence interval = 1.746 to 133.52, P =0 . 0 1 4 )w a st h e
only strong predicator of bladder cancer progression.
Validation of the signature in an independent cohort
We next sought to validate our findings by using gene
expression data from an independent cohort of Eur-
opean patients with bladder cancer [32]. Patients with
NMIBC from this cohort (n = 302) were divided into
two groups according to the expression level of S100A8.
Consistent with our results, progression of NMIBC was
significantly higher in patients with S100A8 expression
levels in the upper 50th percentile than in those with
S100A8 expression levels in the lower 50th percentile
(log-rank test, P < 0.001; Figure 1-C).
We also validated the association of the S100A8-corre-
lated gene signature with disease progression in the Eur-
opean cohort. To overcome the peculiarities of any one
particular prediction algorithm, we applied five different
statistical methods to test the accuracy of our signature-
based prediction of disease progression (Figure 3). We
identified the genes with the greatest difference in
expression level between the HSC and LSC subgroups
in our original cohort (the training set). These genes
were pooled to form a series of classifiers able to esti-
mate the probability that a particular bladder cancer
sample belonged to the HSC or LSC subgroup. The
number of genes in the classifier set was optimized to
minimize misclassification during LOOCV of the tumors
in the training set. The performance of each prediction
model is illustrated in Table 3. When applied to the
European cohort (the test set), all five models produced
consistent prediction patterns. Kaplan-Meier estimations
in the test set revealed significant differences in the risk
of progression between patients in subgroups HSC and
LSC (Figure 3-B).
Biological insights into the signature for disease
progression
To identify the predominant signalling networks active
in the advancement from NMIBC to MIBC, gene net-
work analysis of the 1,015 genes featured in the progres-
sion signature (Figure 2) was carried out using
Ingenuity™ Pathways Analysis software. Of the 1,015
genes, 768 were mapped to gene networks defined by
this tool. This analysis revealed a series of putative net-
works and associated functional categories. The 10 puta-
tive networks with highest scores are listed in Additional
file 1 and their associated functions are illustrated in
Figure 4.
As expected, genes involved in cellular growth and pro-
liferation, cell cycle, cancer, and cell death were
enriched, providing confidence in our results. We also
found that genes involved in cell-mediated immune
responses, immune cell trafficking, humoral immune
Table 1 Baseline characteristics of primary non-muscle
invasive bladder cancer patients
Variable No. of patients (%)
Sex
Male 87 (84.5)
Female 16 (15.5)
Grade
Low 86 (83.5)
High 17 (16.5)
Stage
Ta 23 (22.3)
T1 80 (77.7)
Progression
No 92 (89.3)
Yes 11 (10.7)
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disease were significantly enriched (Figure 4).
Interestingly, among the top 10 putative networks, we
observed functional connectivity between S100A8 and
IL1B in the third network, in which S100A8 is a down-
stream effector of IL1B [37] (Figure 5). The expression
level of IL1B was significantly higher in the HSC than in
the LSC subgroup (two-sample t-test, P < 0.001; Figure
6-B), indicating its potential role in the progression of
NMIBC to MIBC. We also found functional relationship
between S100A8 and S100A9,i nw h i c hS100A9 is a
direct binding partner of S100A8 (Figure 5). S100A9 was
more highly expressed in the HSC than in the LSC sub-
group (two-sample t-test, P < 0.001; Figure 6-C).
Discussion
The data presented in this study demonstrates that the
expression signature of S100A8-correlated genes is able
Figure 1 Expression of S100A8 and progression of non-muscle invasive bladder cancer. A: Expression of S100A8 in 103 patients from the
original cohort. B: Kaplan-Meier curves showing time to progression in the original cohort. C: Kaplan-Meier curves showing time to progression
in the independent European cohort.
Figure 2 Gene expression pattern of S100A8-correlated genes and progression of two clusters. A: Gene expression patterns of S100A8
and its correlated genes. A total of 1,015 genes whose expression patterns are highly correlated with S100A8 were selected for cluster analysis
(Pearson correlation test, P < 0.001, r < -0.3 or r > 0.3). Patients were divided into two groups: high S100A8 cluster (HSC) and low S100A8 cluster
(LSC). B: Kaplan-Meier curves showing time to progression. The progression rate of HSC patients was significantly higher than that of LSC
patients (log-rank test, P < 0.001).
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The validity of this signature as a prognostic indicator
was confirmed by analysis of 302 cancers from an inde-
pendent European cohort. In addition, based on the
results of gene network analysis, we have identified a
putative mechanism that may be responsible for disease
progression.
Although considerable effort has been devoted to the
establishment of a prognostic model of NMIBC that can
provide information concerning survival and treatment
options at diagnosis [1-6], the ability to predict the
course of disease progression for patients with bladder
cancer remains a major clinical challenge. A number of
the molecular markers that have been identified to date
have been explored as potential predictors of disease
progression. Some of these, such as p53, have been sug-
gested to be independent markers, while others do not
appear to be effective as prognostic indicators [4-6].
Thus, there is a crucial need for methods capable of
identifying patients with NMIBC that is likely to develop
into MIBC. In the present study, we developed a
method to predict the progression of primary NMIBC
based on a gene expression signature. We showed that
our method has strong predictive value through multi-
variate regression analysis and a validation study in an
independent cohort. These data underscore the effec-
tiveness of this molecular signature as a prognostic indi-
c a t o ri nN M I B C ,a n ds u g g e s tt h a tt h i ss i g n a t u r ec o u l d
be clinically useful.
The accumulation of recent reports that document the
deregulated expression of calcium-binding proteins of
the S100 family in a variety of human cancers implies
that S100 proteins are required for neoplastic or meta-
static transformation of tumor cells [26]. Previous obser-
vations that S100A8 expression is enhanced in bladder
cancer suggest a role for this protein in the progression
of bladder cancer [21-23]. The data obtained from the
current study demonstrated that upregulation of S100A8
expression was strongly associated with disease progres-
sion. This result substantiates the involvement of
S100A8 during the progression of NMIBC.
Expression of S100A8 is not the only indicator of
S100A8 activity, because it is regulated by many differ-
ent mechanisms. The identification of stable and reliable
human gene-to-gene relationships is an essential step
towards unraveling the interactions and functional cor-
relations between human genes [38]. Therefore, we per-
formed gene network analysis to identify the association
of S100A8-correlated genes with progression of NMIBC.
Strikingly, expression of both S100A8 and its correlated
genes were strong predictors of the progression of blad-
der cancer (Figures 1 and 2). This finding was further
supported by multivariate analysis, which showed that
the molecular signature of S100A8-correlated genes was
Table 2 Multivariate Cox regression analysis for
prediction of disease progression
Variable Progression
HR (95% CI) P-value
Stage (Ta vs. T1) 0.258 (0.032 - 2.083) 0.204
Grade (low vs. high) 2.257 (0.445 - 11.449) 0.326
Number of tumors
Single Reference -
2 to 7 1.684 (0.314 - 9.027) 0.543
>8 4.544 (0.624 - 32.141) 0.129
Size (> 3 cm vs. ≤ 3 cm) 1.933 (0.397 - 9.411) 0.414
Intravesical therapy (Yes
vs. No)
2.141 (0.391 - 11.715) 0.38
S100A8-correlated gene
signature (HSC vs. LSC)
15.225 (1.736 - 133.52) 0.014
Abbreviations: HR, hazards ratio; CI, confidence interval
Table 3 Performance of prediction models
CCP
Class Sensitivity Specificity PPV NPV
HSC 0.92 0.943 0.939 0.926
LSC 0.943 0.92 0.926 0.939
BCC
Class Sensitivity Specificity PPV NPV
HSC 0.88 0.887 0.88 0.887
LSC 0.887 0.88 0.887 0.88
LDA
Class Sensitivity Specificity PPV NPV
HSC 0.9 0.943 0.938 0.909
LSC 0.943 0.9 0.909 0.938
NC
Class Sensitivity Specificity PPV NPV
HSC 0.9 0.962 0.957 0.911
LSC 0.962 0.9 0.911 0.957
SVM
Class Sensitivity Specificity PPV NPV
HSC 0.96 0.962 0.96 0.962
LSC 0.962 0.96 0.962 0.96
Sensitivity and specificity of compound covariate predictor (CCP), Bayesian
compound covariate predictor (BCC), linear discriminator analysis (LDA),
nearest centroid classification (NC), and support vector machines (SVM).
Sensitivity is the probability for a class A sample to be correctly predicted as
class A. Specificity is the probability for a non class A sample to be correctly
predicted as non-A. Positive Predictive Value (PPV) is the probability that a
sample predicted as class A actually belongs to class A. Negative Predictive
Value (NPV) is the probability that a sample predicted as non class A actually
does not belong to class A.
For some class high S100A8 cluster (HSC), if n11 = number of class HSC
samples predicted as HSC, n12 = number of class HSC samples predicted as
low S100A8 cluster (LSC), n21 = number of LSC samples predicted as HSC, and
n22 = number of LSC samples predicted as LSC, then the following
parameters can characterize performance of classifiers: Sensitivity = n11/(n11
+n12), Specificity = n22/(n21+n22), PPV = n11/(n11+n21), and NPV = n22/(n12
+n22).
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Page 5 of 10Figure 3 Independent validation of the prognostic value of the signature. A: The validation strategy used for the construction of prediction
models and the evaluation of predicted outcomes based on gene expression signature. B: Kaplan-Meier plots of progression of NMIBC patients
from an independent European cohort predicted by compound covariate predictor (CCP), Bayesian compound covariate predictor (BCC), linear
discriminator analysis (LDA), nearest centroid classification (NC), and support vector machines (SVM).
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Page 6 of 10Figure 4 Functional classification of S100A8-correlated genes. Classification enrichment was determined using Ingenuity Pathway Analysis
software. The threshold of significance was -log (P = 0.05).
Figure 5 Gene networks enriched with genes associated with S100A8. Gene networks of 1,015 genes that highly correlated with S100A8.
Up- and down-regulated genes in the high S100A8 cluster (HSC) group are indicated in red and green, respectively. The intensity of color is
indicative of the degree of over- or under-expression. Genes without highlighted color are not part of the progression signature but are
associated with the regulated genes. Each line and arrow represents functional and physical interactions between the genes and the direction of
regulation reported in the literature.
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(Table 2). This result suggests that the S100A8-corre-
lated gene signature retains its prognostic relevance
even after additional pathological prognostic features
have been taken into account.
The standard strategy for evaluating the accuracy of
classification methods is application of a training-valida-
tion approach, in which a training set is utilized to iden-
tify the molecular signature and a validation set is used
to estimate the degree of reliability. For the validation
assay, a large sample size is needed before expression
profiling can be utilized in a clinical setting [39]. In the
current study, the accuracy of a predictive S100A8-cor-
related gene signature was tested using five independent
algorithms with gene expression data from a large inde-
pendent European cohort (Figure 3). This result demon-
strated not only a strong association between gene
expression patterns and progression, but also provided
strong evidence of the reliability of the prediction.
Based on an analysis of the S100A8-correlated genes in
the context of gene networks, we identified a putative
role for S100A8 in disease progression of bladder cancer.
Because S100A8 is the downstream target of IL1B [37],
our results strongly support the potential involvement of
IL1B in tumor progression. Recent studies indicate that
IL1B is associated with tumor invasiveness and metastasis
[40,41]. Many of the satellite genes associated with IL1B
(i.e., CXCL2, PLA2G7, CCL11, S100A9, CD163, RNASE7,
and OSM) (Figure 5) participate in inflammatory and
immune responses, which are the best known activities
of IL1B. Previous studies have demonstrated that IL1B
activates inflammation that promotes tumor invasiveness
[40]. It was reported previously that S100A9 is up-regu-
lated in conjunction with S100A8 in many cancers,
including gastric cancer [20], prostate cancer [16,17], and
colorectal cancer [18,19]. Both S100A8 and S100A9 have
been implicated in the regulation of cell proliferation
[16,24] and metastatic processes [25]. Thus, S100A9 may
prove a valuable target for prevention of the migration of
tumor cells to pre-metastatic sites [26].
Our results demonstrate that an expression signature
consisting of S100A8 and its correlated genes can be a
reliable prognostic indicator of progression in NMIBC,
independent of traditional pathologic prognostic para-
meters. The use of this signature as a predictive indica-
tor could potentially enable the prognosis of
heterogeneous NMIBC patients to be determined at
diagnosis, which would allow for individualized treat-
ment and evaluation.
Conclusions
We describe a prognostic molecular signature based on
gene expression of S100A8-correlated genes that can
identify patients with high-risk NMIBC that is likely to
develop into MIBC. Identification of patients with high-
risk NMIBC may improve the effectiveness of currently
available treatments and provide opportunities for the
development of new treatment modalities.
Additional file 1: The list of gene networks. Top10 list of gene
networks constructed by Ingenuity™ Pathway Analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
21-S1.XLS]
Figure 6 Comparison of expression levels between high S100A8 cluster (HSC) and low S100A8 cluster (LSC) patients. Two group box
plot comparing expression levels of S100A8 (A), IL1B (B), and S100A9 (C) in HSC and LSC patients. P-value was obtained by two-sample t-test
between HSC and LSC. The value of r indicates the correlation coefficient value of the gene compared with S100A8.
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NMIBC: (non-muscle invasive bladder cancer); MIBC: (muscle invasive bladder
cancer); TUR: (transurethral resection); LOOCV: (leave-one-out cross
validation); HSC: (high S100A8 cluster); LSC: (low S100A8 cluster).
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